Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Hosted on MSN6d
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) ...